Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence on LinkedIn:
”This marks the end of availability for the only specific reversal agent for apixaban and rivaroxaban in the U.S., shifting reliance back to non-specific options like PCCs or supportive care for managing FXa inhibitor-associated bleeds.”
Qutoing Beyondsight Intelligence‘s post:
”FDA Issues Safety Update on Andexxa — U.S. Withdrawal Announced
The FDA has determined that postmarketing safety data for Andexxa (andexanet alfa), the anticoagulation reversal agent, show that serious thromboembolic risks outweigh its clinical benefits.
AstraZeneca will voluntarily withdraw Andexxa from the U.S. market, with availability ending December 22, 2025.
Key Points:
• Granted accelerated approval in 2018 for reversal of rivaroxaban and apixaban in life-threatening or uncontrolled bleeding
• Approval included a Boxed Warning for thromboembolic risk
• Postmarketing evidence, including ANNEXA-I, raised concerns around thrombotic events and mortality
Why It Matters:
• Highlights how real-world and confirmatory data can fundamentally shift benefit–risk assessments
• Reinforces the FDA’s scrutiny of accelerated approvals when safety signals emerge
• Leaves a gap in anticoagulation reversal options, impacting critical care decision-making
Key Takeaway:
Andexxa’s U.S. withdrawal underscores the power of post-approval evidence in reshaping regulatory outcomes—and the importance of long-term safety surveillance for high-risk biologics.
Follow our page for more such updates.
News Source.”
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 12:30Zain Khalpey: How a Sudden Blockage Causes Myocardial Infarction
-
Sep 23, 2026, 12:16Apurva Popat: When Heparin Triggers Thrombosis
-
Sep 23, 2026, 12:14Zahra Ghasemi: The Power of Voluntary Blood Donation
-
Sep 23, 2026, 12:04Leo Nicolai: Activated Platelets Get Trapped in the Spleen During Thrombosis
-
Sep 23, 2026, 12:01Francisco Chacón-Lozsán: Rethinking PE Risk in 2026
-
Sep 23, 2026, 11:58Ifeanyichukwu Ifechidere: Factor V Leiden Requires Context Beyond the Genetic Result
-
Sep 23, 2026, 11:35Martina Wolff: How Platelet Membrane Protrusions Shape Hemostasis and Thrombosis
-
Sep 23, 2026, 11:28Alejandro González Veliz: Ultrashort DAPT After PCI May Reduce Bleeding Without Increasing Overall Ischemic Events
-
Sep 23, 2026, 11:17High DOAC Adherence After Stroke – International Journal of Stroke